首页 > 抗体蛋白 > 抗体
PerCP/Cyanine5.5 anti-human CD3 Antibody
产品名称:
PerCP/Cyanine5.5 anti-human CD3 Antibody
产品类别:
抗体
产品编号:
300429
产品应用:
300429
[价格]
规格 价格 库存
25tests ¥ 2464 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The CD3 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections4,6,7 and formalin-fixed paraffin-embedded sections11, immunoprecipitation1, activation of T cells2,3,5, Western blotting9, and spatial biology (IBEX)16,17. The LEAF? purified antibody (Endotoxin < 0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 300413, 300414, and 300432). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 300437, 300438, 300465, 300466, 300473, 300474) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin < 0.01 EU/?g).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Salmeron A, et al. 1991. J. Immunol. 147:3047. (IP)
  2. Graves J, et al. 1991. J. Immunol. 146:2102. (Activ)
  3. Lafont V, et al. 2000. J. Biol. Chem. 275:19282. (Activ)
  4. Ryschich E, et al. 2003. Tissue Antigens 62:48. (IHC)
  5. Thompson AG, et al. 2004. J. Immunol. 173:1671. (Activ)
  6. Sakkas LI, et al. 1998. Clin. Diagn. Lab. Immun. 5:430. (IHC)
  7. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  8. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  9. Van Dongen JJM, et al. 1988. Blood 71:603. (WB)
  10. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  11. Pollard, K. et al. 1987. J. Histochem. Cytochem. 35:1329. (IHC)
  12. Luckashenak N, et al. 2013. J. Immunol. 190:27. PubMed
  13. Laurent AJ, et al. 2014. PLoS One. 9:103683. PubMed
  14. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  15. Stoeckius M, et al. 2017. Nat. Methods. 14:865-868. (PG)
  16. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
  17. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
Product Citations
  1. Poonia B, Pauza C 2014. PLoS One. 9:88884. PubMed
  2. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  3. Xu L, et al. 2018. Mol Oncol. 12:269. PubMed
  4. Shoda H, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1308-y. PubMed
  5. Li H, et al. 2022. Front Immunol. 13:988004. PubMed
  6. Nakano M, et al. 2021. Front Immunol. 12:713225. PubMed
  7. Nagafuchi Y, et al. 2016. Sci Rep. 6:29338. PubMed
  8. Yeung Y, et al. 2016. Nat Commun. 7:13376. PubMed
  9. Armour K, et al. 2014. PLoS One. 9:109463. PubMed
  10. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  11. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  12. Rajakumar SA, et al. 2021. Cell Rep Med. 2:100470. PubMed
  13. Li T, et al. 2022. Int J Infect Dis. 122:874. PubMed
  14. Mbiribindi B, et al. 2020. Sci Rep. 10:19973. PubMed
  15. Ciarlo E, et al. 2016. Sci Rep. 6:37944. PubMed
  16. Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed
  17. Scherer SD, et al. 2021. Breast Cancer Res. 23:100. PubMed
  18. Zhang M, et al. 2020. J Cell Mol Med. . PubMed
  19. Jilkova Z, et al. 2017. Mediators Inflamm. 10.1155/2017/3214917. PubMed
  20. van Heerden D, et al. 2021. Int J Mol Sci. 22:. PubMed
  21. Turner AW, et al. 2020. ACS Infect Dis. 6:1719. PubMed
  22. Shen M, et al. 2018. Int J Oncol. 53:317. PubMed
  23. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  24. Ye C, et al. 2017. J Virol. 91:e01389-23. PubMed
  25. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  26. Aydin AM, et al. 2021. Int Immunopharmacol. 94:107481. PubMed
  27. Xu S, et al. 2021. Immunity. . PubMed
  28. Sumitomo S, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.001. PubMed
  29. Vendrame E, et al. 2020. AIDS. 34:801. PubMed
  30. Song R, et al. 2022. Front Immunol. 13:1028246. PubMed
  31. Pritchett J, et al. 2016. J Infect Dis. 214(12):1911-1915. PubMed
  32. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  33. Nakachi S, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1309-x. PubMed
  34. Sicklinger F, et al. 2021. J Clin Invest. 131:. PubMed
  35. Khuzwayo S, et al. 2021. Front Immunol. 12:631410. PubMed
  36. Shehata L, et al. 2019. Cell Rep. 28:3300. PubMed
  37. Landgraf KE, et al. 2020. Commun Biol. 0.330555556. PubMed
  38. Gross C, et al. 2016. Proc Natl Acad Sci U S A. 113: 2973 - 2982. PubMed
  39. K?rner C et al. 2017. Cell host & microbe. 22(1):111-119 . PubMed
  40. Rappazzo CG, et al. 2022. Immunity. 55:1710. PubMed
  41. Fels JM, et al. 2021. Cell. 184(13):3486-3501.e21. PubMed
  42. Dulberger CL et al. 2017. Immunity. 46(6):1018-1029 . PubMed
  43. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  44. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  45. Teirlinck A, et al. 2015. Infect Immun . 83: 3732-3739. PubMed
  46. Shehata L, et al. 2019. Nat Commun. 10:1126. PubMed
  47. Portillo AL, et al. 2021. iScience. 24(6):102619. PubMed
  48. Poznanski SM, et al. 2021. Cell Metabolism. 33(6):1205-1220.e5. PubMed
  49. Ribot J, et al. 2014. J Immunol. 192:2237. PubMed
  50. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  51. Brunk F, et al. 2021. Eur J Immunol. 51:2651. PubMed
RRID
AB_893301 (BioLegend Cat. No. 300429) AB_893299 (BioLegend Cat. No. 300430)

Antigen Details

Structure
Ig superfamily, with the subunits of CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.

Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线